{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 55,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a clinical trial protocol including patient disposition criteria and study endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/31",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.27,
        "x": 0.38,
        "y": 0.32
      },
      "kind": "diagram",
      "text": "BA3011 1.8 mg/kg Q2W, 2Q3W, 3Q4W; BA3011 + nivolumab 1.8 mg/kg Q2W",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8c6283b-d65c-4356-abc1-5f985367acbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.36,
        "x": 0.06,
        "y": 0.31
      },
      "kind": "list",
      "text": "Patient disposition: Confirmed locally advanced or metastatic NSCLC, Age >= 18 years, ECOG performance status of 0 or 1, Treatment failure of a PD-1/L1 inhibitor or approved therapy for EGFR or ALK genomic tumor aberrations, AXL+ tumor staining (TmPS >= 1%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34867e5b-192f-4c3e-b417-e37430c5c653",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.67,
        "y": 0.31
      },
      "kind": "list",
      "text": "Primary endpoint: ORR via RECIST v1.1, Incidence and severity of AEs. Secondary endpoints: DOR, PFS, BOR, DCR, TTR, OS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e1b2721-a421-4916-9469-8a21f069aa42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Multicenter, Phase 2, open-label trial evaluating the efficacy and safety of BA3011 alone and in combination with nivolumab",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e1c45e9-73bd-4c82-83dd-db3a4003ffa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.068
      },
      "kind": "source-note",
      "text": "*Coded by MedDRA and graded according to NCI CTCAE v5",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00bbe620-aba8-4b9f-824a-24450d453e74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "CAB-AXL (BA3011) – Phase 2 Non-Small Cell Lung Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a1a3502-c66c-4029-af40-b5812710df6d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2b352a49-1a89-4e27-8a24-e170017a1690",
      "evidence": "list/bullet: Patient disposition: Confirmed locally advanced or metastatic NSCLC, Age >= 18 years, ECOG performance status of 0 or 1, Treatment failure of a PD-1/L1 inhibitor or approved therapy for EGFR or ALK genomic t",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}